Pharma BD Deal Intelligence

Salix Pharmaceuticals, Ltd. / Oceana Therapeutics, Inc.

2011 · Acquisition/Merger · $300M · Complete

Announcement Sentiment

Strongly positive

Salix acquired Oceana Therapeutics in an all-cash $300M deal to gain Solesta (FDA-approved May 2011 for fecal incontinence) and Deflux (pediatric VUR). Closed December 20, 2011. Solesta peak-sales potential cited at >$500M.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Dilutive

Pipeline outcome

Mixed

Assessment window: 5yr post-close.

Key facts

Announced Nov 08, 2011
Closed Dec 20, 2011
Deal value $300M
Deal type Acquisition/Merger
Therapeutic area Fecal incontinence; vesicoureteral reflux (pediatric)
Indications Fecal incontinence; vesicoureteral reflux (pediatric)
Key assets Solesta (dextranomer/hyaluronic acid); Deflux
Mechanism Bulking agent injectable hydrogels (dextranomer/hyaluronic acid)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals